Literature DB >> 11479399

Gabapentin withdrawal syndrome.

J W Norton1.   

Abstract

Gabapentin (GBP) has gained wide acceptance in the treatment of pain, migraine, bipolar illness, and epilepsy. It has a relatively benign side effect profile, lacks significant drug interactions, is not liver metabolized, and is renally excreted. Herein three cases are presented that demonstrate withdrawal symptoms after abrupt discontinuation of GBP. Clinicians are encouraged to taper GBP dosage, especially when patients have taken high doses, and to warn patients of possible adverse effects of abruptly discontinuing GBP themselves.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479399     DOI: 10.1097/00002826-200107000-00011

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

Review 1.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.

Authors:  Cory Toth
Journal:  Ther Adv Drug Saf       Date:  2014-02

3.  All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

4.  Gabapentin Use in the Neonatal Intensive Care Unit.

Authors:  Laura Edwards; Stephen DeMeo; Chi D Hornik; C Michael Cotten; P Brian Smith; Carolyn Pizoli; Julie M Hauer; Margarita Bidegain
Journal:  J Pediatr       Date:  2015-11-11       Impact factor: 4.406

5.  A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.

Authors:  Kirk J Brower; Hyungjin Myra Kim; Stephen Strobbe; Maher A Karam-Hage; Flavia Consens; Robert A Zucker
Journal:  Alcohol Clin Exp Res       Date:  2008-06-06       Impact factor: 3.455

Review 6.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

7.  Gabapentin Prevents Progressive Increases in Excitatory Connectivity and Epileptogenesis Following Neocortical Trauma.

Authors:  D K Takahashi; Sha Jin; D A Prince
Journal:  Cereb Cortex       Date:  2018-08-01       Impact factor: 5.357

8.  Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

9.  Administration of four different doses of gabapentin reduces awakening from breakthrough pain and adverse effects in outpatients with neuropathic pain during the initial titration.

Authors:  Jong-Yeun Yang; Won Il Lee; Woo-Kyung Shin; Cheul Hong Kim; Seong-Wan Baik; Kyung-Hoon Kim
Journal:  Korean J Anesthesiol       Date:  2013-07-19

Review 10.  Gabapentin in acute postoperative pain management.

Authors:  Connie Y Chang; Chaitanya K Challa; Janki Shah; Jean Daniel Eloy
Journal:  Biomed Res Int       Date:  2014-04-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.